SFB1530 receives positive funding decision


The collaborative research center (SFB) 1530 received a positive funding decision and will now start working on deciphering the molecular underpinnings of malignant lymphoma.

C. Reinhardt, who together with T. Oellerich serves as the vice speaker of this consortium, which is led by M. Hallek, will contribute a project that aims at developing novel pre-clinical model systems, to search for genotype-specific actionable vulnerabilities. 

Further information: https://medfak.uni-koeln.de/service/kommunikation/pressemitteilungen/neuer-sonderforschungsbereich-aus-dem-bereich-der-lymphom-und-entzuendungsforschung